WO2011115456A3 - 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 - Google Patents

자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 Download PDF

Info

Publication number
WO2011115456A3
WO2011115456A3 PCT/KR2011/001900 KR2011001900W WO2011115456A3 WO 2011115456 A3 WO2011115456 A3 WO 2011115456A3 KR 2011001900 W KR2011001900 W KR 2011001900W WO 2011115456 A3 WO2011115456 A3 WO 2011115456A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfr2
fusion protein
tweak
tweakr fusion
prophylaxis
Prior art date
Application number
PCT/KR2011/001900
Other languages
English (en)
French (fr)
Other versions
WO2011115456A2 (ko
Inventor
박영우
조기원
유석호
유정
김동진
윤선하
송은정
이은경
오진미
조규원
조미라
김호연
박미경
오혜좌
박진실
우윤주
변재경
유준걸
Original Assignee
한국생명공학연구원
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원, 가톨릭대학교 산학협력단 filed Critical 한국생명공학연구원
Priority to US13/635,868 priority Critical patent/US8916525B2/en
Publication of WO2011115456A2 publication Critical patent/WO2011115456A2/ko
Publication of WO2011115456A3 publication Critical patent/WO2011115456A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 TNFR2-TWEAKR 융합 단백질에 관한 것으로서, 보다 상세하게는 자가 면역 질환의 하나인 자가 면역 관절염의 주요 병인으로 알려진 TNF-α와 TWEAK에 대한 이중 길항제의 역할을 하는 TNFR2-TWEAKR 융합 단백질을 유효성분으로 포함하는 조성물을 Th17 세포에 처리하였을 때, 염즘성 사이토카인 IL-17의 분비가 감소되었으며, Treg 세포에서 생성되는 항염증성 사이토카인 IL-10의 분비가 증가하며, 또한 이러한 효과가 TNFR2-Fc와 TWEAK-Fc 단일 단백질보다 TNFR2-TWEAKR 융합 단백질의 효과가 뛰어날 뿐만 아니라, CIA 관절염 유발 마우스에서 관절염의 치료 효과뿐만 아니라, 면역 억제 세포인 Treg 세포의 발현을 증가시켜 자가 면역 관절염의 치료효과 나타내므로, 본 발명에 따른 TNFR2-TWEAKR 융합 단백질은 자가 면역 질환의 예방 및 치료 효과를 갖는 조성물의 유효성분으로서 유용하게 사용될 수 있다.
PCT/KR2011/001900 2010-03-19 2011-03-18 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 WO2011115456A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/635,868 US8916525B2 (en) 2010-03-19 2011-03-18 TNF-A and TWEAK dual antagonist for the prophylaxis and treatment of autoimmune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100024699A KR101004362B1 (ko) 2010-03-19 2010-03-19 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
KR10-2010-0024699 2010-03-19

Publications (2)

Publication Number Publication Date
WO2011115456A2 WO2011115456A2 (ko) 2011-09-22
WO2011115456A3 true WO2011115456A3 (ko) 2012-01-26

Family

ID=43513450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001900 WO2011115456A2 (ko) 2010-03-19 2011-03-18 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제

Country Status (3)

Country Link
US (1) US8916525B2 (ko)
KR (1) KR101004362B1 (ko)
WO (1) WO2011115456A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
CN103298827B (zh) 2007-08-17 2017-05-31 诺华股份有限公司 环状酯肽
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
CN111100211B (zh) * 2019-01-30 2022-04-08 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110853A1 (en) * 1999-12-20 2002-08-15 Wiley Steven R. TWEAK receptor
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
US20080175896A1 (en) * 2006-12-01 2008-07-24 Winkles Jeffrey A Tweak-pseudomonas exotoxin a fusion protein for cancer therapy
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
WO2010003108A2 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
WO2007009233A2 (en) 2005-07-18 2007-01-25 University Of Manitoba Peptide-based cytokine vaccines in the treatment of autoimmune and inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110853A1 (en) * 1999-12-20 2002-08-15 Wiley Steven R. TWEAK receptor
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
US20080175896A1 (en) * 2006-12-01 2008-07-24 Winkles Jeffrey A Tweak-pseudomonas exotoxin a fusion protein for cancer therapy
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
WO2010003108A2 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS

Also Published As

Publication number Publication date
KR101004362B1 (ko) 2010-12-28
US20130017226A1 (en) 2013-01-17
WO2011115456A2 (ko) 2011-09-22
US8916525B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
WO2011115456A3 (ko) 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
MX2010003574A (es) Anticuerpos il-23.
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EP3428182A3 (en) Anti-inflammatory peptides and composition comprising the same
EP3428181A3 (en) Anti-inflammatory peptides and composition comprising the same
WO2011028344A3 (en) Interleukin-1 receptor antagonist compositions and methods of making and using same
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
WO2007044534A3 (en) Vegf analogs and methods of use
BR112012021337A2 (pt) formulações de apixaban.
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
IN2014DN10386A (ko)
WO2010115998A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
MX2008013508A (es) Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
MY161390A (en) Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EA201400089A1 (ru) Конститутивно активные мутанты рецептора абк (абсцизовой кислоты)
WO2008149354A3 (en) Agents for the treatment of inflammatory diseases and methods of using same
WO2014210037A3 (en) A composition of mesenchymal stem cells
WO2014141210A3 (en) Multifunctional immature dental pulp stem cells and therapeutic applications
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
WO2015164364A3 (en) Methods to manipulate alpha-fetoprotein (afp)
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11756587

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13635868

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11756587

Country of ref document: EP

Kind code of ref document: A2